ElizabethR.PlimackMDMS

Genitourinary Oncology

Chief, Division of Genitourinary Medical Oncology. Director, Genitourinary Clinical Research. Associate Professor, Department of Hematology/Oncology.

Join to view full profile

Dr. Plimack is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Plimack's full profile

Already have an account?

Office
333 Cottman Ave
Fox Chase Cancer Center
Philadelphia, PA 19111
Phone+1 215-728-6900

Fax+1 215-728-3639
Is this information wrong?

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
NYU Grossman School of MedicineResidency, Internal Medicine, 2002 - 2005
New York University School of MedicineClass of 2002

Certifications & Licensure

PA State Medical License 2008 - 2024
TX State Medical License 2005 - 2008
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Whos Who in Medicine and Healthcare Marquis Whos Who

Clinical Trials

Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
Dose Dense MVAC for Muscle Invasive Bladder Cancer Start of enrollment: 2009 Dec 07
Completed
Phase 2
Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma Start of enrollment: 2010 Oct 01
Completed
Phase 1
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma Start of enrollment: 2017 Nov 27
Recruiting
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Corrigendum to "Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 St...
Plimack, E., Powles, T., Stus, V., Gafanov, R., Nosov, D., Waddell, T., Alekseev, B., Pouliot, F., Melichar, B., Soulières, D., Borchiellini, D., McDermott, R., Vynnyc...> ;European Urology. 2024 Feb 1
2 citations
Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort.
Eric Jonasch, Todd M Bauer, Kyriakos P Papadopoulos, Elizabeth R Plimack, Jaime R Merchan, David F McDermott, M Dror Michaelson, Leonard J Appleman, Ananya Roy, Rodolf...> ;European Journal of Cancer. 2024 Jan 1
LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma.
Toni K Choueiri, Thomas Powles, Martin H Voss, Elizabeth R Plimack, Howard Gurney, Yue Song, Rodolfo F Perini, Karla Rodriguez-Lopez, Brian I Rini> ;Future Oncology. 2023 Dec 1
1 citations
Harnessing potent therapies with care: enfortumab vedotin plus pembrolizumab for advanced-stage urothelial carcinoma.
Pooja Ghatalia, Elizabeth R Plimack> ;Nature Reviews. Clinical Oncology. 2023 Dec 1
Corrigendum to "Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 St...
Elizabeth R Plimack, Thomas Powles, Viktor Stus, Rustem Gafanov, Dmitry Nosov, Tom Waddell, Boris Alekseev, Frédéric Pouliot, Bohuslav Melichar, Denis Soulières, Delph...> ;European Urology. 2023 Nov 1
2 citations
A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumors.
Matthew Zibelman, Alexander W MacFarlane 4th, Kimberly Costello, Thomas McGowan, John O'Neill, Rutika Kokate, Hossein Borghaei, Crystal S Denlinger, Efrat Dotan, Danie...> ;Nature Communications. 2023 Jul 27
6 citations
Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study.
Elizabeth R Plimack, Thomas Powles, Viktor Stus, Rustem Gafanov, Dmitry Nosov, Tom Waddell, Boris Alekseev, Frédéric Pouliot, Bohuslav Melichar, Denis Soulières, Delph...> ;European Urology. 2023 Nov 1
Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808.
Bradley C Carthon, Se Eun Kim, David F McDermott, Janice P Dutcher, Maneka Puligandla, Judith Manola, Michael Pins, Michael A Carducci, Elizabeth R Plimack, Leonard J ...> ;Clinical Genitourinary Cancer. 2023 Oct 1
1 citations
Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer.
Ravi A Madan, Marijo Bilusic, Mark N Stein, Renee N Donahue, Philip M Arlen, Fatima Karzai, Elizabeth Plimack, Yu-Ning Wong, Daniel M Geynisman, Matthew Zibelman, Tina...> ;The Oncologist. 2023 Jul 5
5 citations
A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy.
H Josh Jang, Galen Hostetter, Alexander W Macfarlane, Zachary Madaj, Eric A Ross, Toshinori Hinoue, Justin R Kulchycki, Ryan S Burgos, Mahvish Tafseer, R Katherine Alp...> ;Clinical Cancer Research. 2023 Jun 1
2 citations
Patients' Perceptions Regarding the Relevance of Items Contained in the Functional Assessment of Cancer Therapy Kidney Symptom Index-19.
Cristiane Decat Bergerot, Jasnoor Malhotra, Paulo Bergerot, Errol J Philip, Daniela V Castro, JoAnn Hsu, Augusto Cesar de Andrade Mota, Andressa Cardoso de Azeredo, Jo...> ;The Oncologist. 2023 Jun 2
2 citations
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B).
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, David F McDermott, Mehmet A Bilen, Mark Stein, Jeffrey A Sosman, Robert Alter, Elizabeth R Plimack, Moshe C Ornstein,...> ;Journal for Immunotherapy of Cancer. 2023 Mar 1
1 citations
What's in a Name: An Analysis of Gender-Based Acronyms in Clinical Trials.
Laura Bukavina, Mohit Sindhani, Shreyas S Joshi, Elizabeth Plimack, Andres Correa, Nicole Uzzo, Alexander Kutikov, Robert Uzzo> ;Annals of Surgical Oncology. 2023 May 1
8 citations
A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasi...
Noah M Hahn, Michael A O'Donnell, Jason A Efstathiou, Marianna Zahurak, Gary L Rosner, Jeff Smith, Max R Kates, Trinity J Bivalacqua, Phuoc T Tran, Daniel Y Song, Alex...> ;European Urology. 2023 Jun 1
20 citations
Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up.
A V Balar, D E Castellano, P Grivas, D J Vaughn, T Powles, J Vuky, Y Fradet, J-L Lee, L Fong, N J Vogelzang, M A Climent, A Necchi, D P Petrylak, E R Plimack, J Z Xu, ...> ;Annals of Oncology. 2023 Mar 1
2 citations
Platinum-Free Systemic Therapy in First-Line Metastatic Urothelial Carcinoma: Mirage or Oasis in the Platinum Desert?
Elizabeth R Plimack, Matthew R Zibelman> ;Journal of Clinical Oncology. 2023 Jan 1
10 citations
Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer.
Jeffrey S Damrauer, Wolfgang Beckabir, Jeff Klomp, Mi Zhou, Elizabeth R Plimack, Matthew D Galsky, Petros Grivas, Noah M Hahn, Peter H O'Donnell, Gopa Iyer, David I Qu...> ;Nature Communications. 2022 Nov 4
2 citations
Comparative cost-effectiveness of neoadjuvant chemotherapy regimens for muscle-invasive bladder cancer: Results according to VESPER data.
Daniel D Joyce, Kevin M Wymer, Vidit Sharma, James P Moriarty, Bijan J Borah, Daniel M Geynisman, Elizabeth R Plimack, Brian A Costello, Lance C Pagliaro, Stephen A Bo...> ;Cancer. 2022 Dec 15
11 citations
Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma.
Kevin K Zarrabi, Elizabeth Handorf, Benjamin Miron, Matthew R Zibelman, Fern Anari, Pooja Ghatalia, Elizabeth R Plimack, Daniel M Geynisman> ;The Oncologist. 2023 Feb 8
The past, present, and future of pT0 in bladder cancer clinical trials.
Jared P Schober, Elizabeth Plimack, Daniel M Geynisman, Matthew Zibelman> ;Current Opinion in Urology. 2022 Sep 1
Adding a Fourth Modality to Trimodal Therapy for Muscle-invasive Bladder Cancer.
Pooja Ghatalia, Elizabeth R Plimack> ;European Urology. 2022 Nov 1
81 citations
NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022.
Thomas W Flaig, Philippe E Spiess, Michael Abern, Neeraj Agarwal, Rick Bangs, Stephen A Boorjian, Mark K Buyyounouski, Kevin Chan, Sam Chang, Terence Friedlander, Rich...> ;Journal of the National Comprehensive Cancer Network. 2022 Aug 1
14 citations
Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma.
Jens Bedke, Brian I Rini, Elizabeth R Plimack, Viktor Stus, Rustem Gafanov, Tom Waddell, Dimitry Nosov, Frederic Pouliot, Denis Soulières, Bohuslav Melichar, Ihor Vynn...> ;European Urology. 2022 Oct 1
1 citations
Neoadjuvant Chemotherapy with Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Patients with Muscle-invasive Bladder Cancer: A Retrospective Age-st...
Gregory Hemenway, Bianca Lewis, Pooja Ghatalia, Fern Anari, Elizabeth R Plimack, Rutika Kokate, Elizabeth Handorf, Mengying Deng, Daniel M Geynisman, Matthew Zibelman> ;European Urology Oncology. 2023 Aug 1
Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who received second-line immune checkpoint inhibitors.
Benjamin Miron, Elizabeth Handorf, Kevin Zarrabi, Matthew R Zibelman, Fern Anari, Pooja Ghatalia, Elizabeth R Plimack, Daniel M Geynisman> ;Urologic Oncology. 2022 Oct 1
Join now to see all

Journal Articles

Pan-Tumor Genomic Biomarkers for PD-1 Checkpoint Blockade–Based Immunotherapy
Jonathan Cheng, Patrick A Ott, Elizabeth R Plimack, Antoni Ribas, Andrew Joe, Science Magazine

Press Mentions

ASCO GU 2023: Update on Bladder-Sparing Treatment Trial: RETAIN BLADDERFebruary 15th, 2023
Neoadjuvant Chemotherapy Shows “Clear Benefit” in Upper Tract Urothelial CarcinomaJanuary 26th, 2023
Practice-Changing Presentations in Renal Cell Carcinoma: Insights from ASCO® 2021July 5th, 2021
Join now to see all